Analyst Benjamin Jackson CFA from Jefferies maintained a Buy rating on Galderma Group AG (GALD – Research Report) and keeping the price target at CHF112.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Benjamin Jackson CFA has given his Buy rating due to a combination of factors that suggest strong future prospects for Galderma Group AG. The company is experiencing a promising uptake of its product, Nemluvio, particularly among biologics-naive patients, which has exceeded initial expectations. This early success indicates potential for significant market penetration and revenue growth.
Additionally, Galderma is poised to capitalize on growth opportunities in the injectable aesthetics market, where there is substantial room for expansion. The company’s strategic focus on innovation and potential mergers and acquisitions further supports its growth trajectory. These elements collectively contribute to a positive outlook, justifying the Buy rating.